Powered by

Black Diamond Therapeutics Closes $85 Million Series B Financing

Jan 09, 2019 - PR Newswire

PR Newswire

 Black Diamond Therapeutics, Inc., a biotechnology company developing next-generation precision medicines for cancer, today announced the completion of an oversubscribed Series B financing of $85 million co-led by New Enterprise Associates and RA Capital Management. Additional new investors NexTech Invest, The Invus Group and Perceptive Advisors joined founding investor Versant Ventures in the round. Following Black Diamond's recent debut after operating in stealth mode in Ver...